Core Viewpoint - The company, Haizheng Pharmaceutical (600267.SH), is publicly listing the 100% equity stake of its wholly-owned subsidiary, Zhejiang Pharmaceutical Industry Co., Ltd., for transfer through a property rights exchange [1] Summary by Sections - **Equity Transfer Details** - The assessed value of the 100% equity stake in Zhejiang Pharmaceutical Industry Co., Ltd. is 392 million yuan, with a proposed public listing base price of 430 million yuan [1] - The company submitted the application for the equity transfer on November 10, 2025, to the Taizhou Property Rights Exchange [1] - The official listing period for the equity transfer is from November 11, 2025, to December 8, 2025 [1]

Core Viewpoint - The company, Haizheng Pharmaceutical (600267.SH), is publicly listing the 100% equity stake of its wholly-owned subsidiary, Zhejiang Pharmaceutical Industry Co., Ltd., for transfer through a property rights exchange [1] Group 1 - The assessed value of the 100% equity stake in the subsidiary is 392 million yuan, with a proposed public listing base price of 430 million yuan [1] - The company submitted the application for the equity transfer on November 10, 2025, to the Taizhou Property Rights Exchange [1] - The official listing period for the equity transfer is from November 11, 2025, to December 8, 2025 [1]

海正药业公告，公司已于2025年11月10日向台州市产权交易所有限公司提交了省医药公司100%股权转 让的挂牌申请，正式挂牌期自2025年11月11日至2025年12月8日止。省医药公司100%股权对应的评估价 值为3.92亿元，拟以4.3亿元作为对外公开挂牌底价。 ...

Core Viewpoint - Zhejiang Haizheng Pharmaceutical and Zhejiang Shengzhao Pharmaceutical announced a joint investment of 2.3 billion yuan to establish a joint venture aimed at the high-end complex formulation international market, marking a new chapter in the globalization of China's complex formulations [1][4]. Group 1: Joint Venture and Market Strategy - The joint venture targets the high-end complex formulation market, which is known for its technical and production challenges [2]. - Shengzhao Pharmaceutical has successfully developed six technology platforms and has products approved for market, indicating a concentrated harvest period for its R&D efforts [2][3]. - Haizheng Pharmaceutical has a mature commercial system and international export platform, which will support the joint venture's growth [3]. Group 2: Production Challenges and Solutions - Shengzhao Pharmaceutical has faced challenges in scaling production, traditionally relying on CMO models, which could delay market entry [2][3]. - The joint venture aims to overcome these challenges by leveraging Haizheng's manufacturing capabilities and Shengzhao's R&D strengths [3][4]. - The new production technology developed by Shengzhao will allow for batch production every 5-7 days, significantly increasing output and reducing costs [5][6]. Group 3: Future Plans and Market Potential - The joint venture plans to register by the end of the year, begin construction in 2026, and aim for the first product approval by 2030 [8]. - The global complex injection market is projected to reach a scale of 100 billion USD by 2030, with China's market expected to grow to 77.9 billion yuan by 2030 [8][9]. - The strategy includes launching mature products in international markets first, followed by the development of improved drugs [9][10]. Group 4: Innovation and Clinical Relevance - The focus of the joint venture will be on developing innovative formulations that address clinical needs rather than merely changing dosage forms [10]. - The collaboration aims to set a benchmark for high-end manufacturing in China and establish a leading position in the global complex formulation market [7][10].

Core Viewpoint - Recent data indicates a significant rise in influenza activity in China, with a notable increase in patients visiting hospitals for treatment, prompting the need for early antiviral therapy and consideration of various factors in drug selection [1][2][3] Group 1: Influenza Activity - The latest report from the Chinese Center for Disease Control and Prevention shows a marked increase in influenza activity, particularly in southern provinces, with the percentage of influenza-like illness (ILI) cases reported at 4.6%, up from 4.1% the previous week [2] - Northern provinces reported an ILI percentage of 5.1%, significantly higher than the previous week's 3.7% and above levels from 2022, 2023, and 2024 [2] - A total of 347 influenza-like illness outbreaks were reported nationwide, with 245 cases identified as A(H3N2) [2] Group 2: Treatment and Drug Approval - The increase in influenza cases has led to a rise in hospital visits, particularly in pediatric departments, with doctors recommending early antiviral treatment within 48 hours of symptom onset [4] - Oseltamivir remains the preferred antiviral treatment, especially for children and immunocompromised patients, with over 120 approvals for related products from various companies [4][5] - The market for oseltamivir is dominated by Dongyangguang Pharmaceutical, holding over 70% market share in the past three years [4] Group 3: New Drug Developments - Several new RNA polymerase inhibitors have been approved in China, with the year 2025 being referred to as the "Year of Domestic Influenza New Drugs" [1][6] - Roche's Marbofloxacin has seen a significant increase in demand, with supply pressures leading to local production initiatives [6][7] - Other domestic companies, such as Qingfeng Pharmaceutical and Zhongsheng Pharmaceutical, have also launched new antiviral drugs, contributing to a broader range of treatment options for influenza [7][8] Group 4: Market Dynamics - The price of Marbofloxacin ranges from 195 to 234 yuan per pack, with no adjustments made by Roche despite increased demand [7] - Companies like Haizheng Pharmaceutical have reported a significant rise in demand for their antiviral products, with ongoing supply guarantees in place [8][9] - The market is seeing increased competition as more domestic firms enter the RNA polymerase inhibitor space, with several products currently in clinical trials or awaiting approval [9]

Core Viewpoint - The complex injection market is emerging as a new avenue for Chinese pharmaceutical companies to break into international markets, driven by high technical barriers and significant clinical value [1][2]. Group 1: Company Developments - Haizheng Pharmaceutical and Zhejiang Shengzhao Pharmaceutical Technology Co., Ltd. have established a joint venture focused on the development, production, and global commercialization of 11 complex injection products, including generics and modified new drugs [1]. - The chairman of Haizheng Pharmaceutical emphasized that complex injections are a key area for differentiated development and an important step in the company's internationalization strategy [1][2]. Group 2: Market Potential - According to Frost & Sullivan, the market size for complex injections in China is projected to reach 40.8 billion yuan by 2025 and 77.9 billion yuan by 2030, with a compound annual growth rate (CAGR) exceeding 13% [1]. - Unlike ordinary generics, complex injections maintain higher price levels due to their technical barriers, providing more growth opportunities for companies [1][2]. Group 3: Challenges in the Industry - The production of complex injections presents significant technical challenges, including high precision in process control and long-term stability verification, with few companies capable of large-scale industrial production [2][3]. - International market entry poses another challenge, as companies must navigate stringent regulatory requirements, particularly in markets like Europe and the U.S. [3]. - The competitive landscape includes companies from Israel, India, and the U.S., necessitating Chinese firms to establish differentiated advantages through technological breakthroughs and large-scale production [3].

证券日报网讯 11月6日晚间，海正药业发布公告称，近日，公司控股子公司浙江海正动物保健品有限公 司收到中华人民共和国农业农村部核准签发的复方制霉菌素软膏、托曲珠利混悬液兽药产品批准文号批 件。 （文章来源：证券日报） ...

证券代码：600267 证券简称：海正药业 公告编号：临 2025-67 号 浙江海正药业股份有限公司 关于子公司获得兽药产品批准文号批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江海正药业股份有限公司（以下简称"公司"）控股子公司浙江海 正动物保健品有限公司（以下简称"海正动保公司"）收到中华人民共和国农业 农村部核准签发的复方制霉菌素软膏、托曲珠利混悬液兽药产品批准文号批件。 现就相关情况公告如下： 一、批件基本信息 （一）通用名称：复方制霉菌素软膏 兽药产品批准文号：兽药字 110803270 批准文号有效期：2025-09-05 至 2030-09-04 商品名称：尔特宁 含量规格：10g：制霉菌素 100 万单位+硫酸新霉素 3.5 万单位+氯菊酯 100mg+ 曲安奈德 10mg 企业名称：浙江海正动物保健品有限公司 生产地址：浙江省杭州市富阳区东洲街道高尔夫路 208 号 （二）托曲珠利混悬液 兽药产品批准文号：兽药字 110803301 批准文号有效期：2025-10-24 至 2030- ...

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for two veterinary drug products, which will enhance its product line and market competitiveness in the veterinary medicine sector [1] Product Approval - The approved products include Compound Streptomycin Ointment, which is used to treat otitis externa in dogs and cats caused by bacteria sensitive to neomycin, fungi sensitive to streptomycin, and ear mites sensitive to chlorpyrifos [1] - The second product, Tocilizumab Suspension, is intended for the prevention of coccidiosis in piglets and calves [1] Strategic Implications - The approval of these veterinary drug products will enrich the company's veterinary medicine product line and structure, facilitating its strategic layout in the veterinary drug sector [1] - This development is expected to enhance the company's market competitiveness within the veterinary medicine industry [1]

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for two veterinary drug products, which will enhance its product line and market competitiveness in the veterinary medicine sector [1] Group 1 - The company’s subsidiary, Zhejiang Haizheng Animal Health Products Co., Ltd., has been granted approval for the compound streptomycin ointment and torquatozole suspension veterinary drug products [1] - The approval will enrich the company's veterinary drug product line and structure, supporting its strategic layout in the veterinary medicine sector [1] - This development is expected to improve the company's market competitiveness in the veterinary drug market [1]